Aurinia Pharmaceuticals Inc. announced preliminary unaudited revenue results for the three months and full year ended December 31, 2022. For the three months, the company reported net revenue of $28.4 million. For the three months ended December 31, 2022, preliminary unaudited net revenues included net product revenues of approximately $28.3 million and license and collaboration revenue of approximately $0.1 million.

For the full year, the company reported net revenues of $134.0 million. For the full year ended December 31, 2022, preliminary unaudited net revenues included net product revenues of approximately $103.5 million and license and collaboration revenue of approximately $30.5 million.